Aldeyra Therapeutics ALDX
NASDAQ ALDX
$0.68 -0.06 (-7.74%)
As of: Oct 21, 2026 · 2:40 PM EDT

Aldeyra Therapeutics (ALDX) Current Deferred Revenue (2024 - 2025)

Updated

Aldeyra Therapeutics (ALDX) recorded Current Deferred Revenue of $6 million in Q4 2025, unchanged from $6 million a year earlier.

Analysis

Aldeyra Therapeutics (ALDX) Current Deferred Revenue (2024 - 2025) Analysis & Trends

Starting with Q2 2024, Aldeyra Therapeutics' Current Deferred Revenue history includes 4 quarters.

  • Across earlier years, Current Deferred Revenue came in at $6 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.90 Bn 1,105.48 Bn 19.71 Bn
2 Johnson & Johnson 617.06 Bn 535.59 Bn 17.26 Bn
3 AbbVie 501.38 Bn 474.49 Bn 12.70 Bn
4 Merck 367.41 Bn 321.79 Bn 12.21 Bn
5 Novartis Ag 297.92 Bn 261.91 Bn 11.24 Bn
6 Astrazeneca 261.31 Bn 235.00 Bn 12.86 Bn
7 Amgen 236.29 Bn 191.69 Bn 7.24 Bn
8 Gilead Sciences 190.40 Bn 164.60 Bn 6.22 Bn
9 Pfizer 169.55 Bn 116.19 Bn 10.94 Bn
10 Aldeyra Therapeutics 41.02 Mn -214.41 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 6.00 Mn
Dec 31, 2024 6.00 Mn
Sep 30, 2024 6.00 Mn
Jun 30, 2024 6.00 Mn
API Access

Aldeyra Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ALDX&period=max&api_key=YOUR_API_KEY